An Escherichia coli O157-Specific Engineered Pyocin Prevents and Ameliorates Infection by E. coli O157:H7 in an Animal Model of Diarrheal Disease
Ritchie, Jennifer M.
Greenwich, Jennifer L.
Davis, Brigid M.
Bronson, Roderick T.
Williams, Steven R.
Waldor, Matthew K.
MetadataShow full item record
CitationRitchie, Jennifer M., Jennifer L. Greenwich, Brigid M. Davis, Roderick T. Bronson, Dana Gebhart, Steven R. Williams, David Martin, Dean Scholl, and Matthew K. Waldor. 2011. “An Escherichia Coli O157-Specific Engineered Pyocin Prevents and Ameliorates Infection by E. Coli O157:H7 in an Animal Model of Diarrheal Disease.” Antimicrobial Agents and Chemotherapy 55 (12): 5469–74. https://doi.org/10.1128/aac.05031-11.
AbstractAvR2-V10.3 is an engineered R-type pyocin that specifically kills Escherichia coli O157, an enteric pathogen that is a major cause of food-borne diarrheal disease. New therapeutics to counteract E. coli O157 are needed, as currently available antibiotics can exacerbate the consequences of infection. We show here that orogastric administration of AvR2-V10.3 can prevent or ameliorate E. coli O157:H7-induced diarrhea and intestinal inflammation in an infant rabbit model of infection when the compound is administered either in a postexposure prophylactic regimen or after the onset of symptoms. Notably, administration of AvR2-V10.3 also reduces bacterial carriage and fecal shedding of this pathogen. Our findings support the further development of pathogen-specific R-type pyocins as a way to treat enteric infections.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:41483559
- HMS Scholarly Articles